For prescribing information and adverse event reporting, click here

This section of the website is for UK Healthcare Professionals only. 
If you are not a Healthcare Professional, please click here.

This website has been commissioned by Ipsen UK and is intended for a UK audience.

All materials

Identification and management of adverse reactions with cabozantinib in patients with advanced renal cell carcinoma

Renal Cell Carcinoma File
17 pages

A guide for healthcare professionals

CBZ-UK-000342 | November 2024

Identification and management of adverse reactions with cabozantinib in patients with advanced renal cell carcinoma
Explore more Renal Cell Carcinoma Resources

Explore more Renal Cell Carcinoma Resources

Browse

To access relevant information about Renal Cell Carcinoma, please confirm the following:

I am a UK Healthcare Professional

This section is for UK healthcare professionals only. Contains promotional information

I am a UK Healthcare Professional

Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 
01753 627777.

I am a patient

This section provides information to support patients that have been prescribed Cabozantinib Ipsen.

I am a patient

I am a member of the general public

This section is for members
of the general public.

I am a member of the general public

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Side effects should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777. By reporting side effects, you can help provide more information on the safety of this medicine.